No thanks: Roche backs out of EGFR-re­lat­ed pro­tein de­graders in re­vised deal with C4

Roche and C4 Ther­a­peu­tics have been col­lab­o­ra­tors since 2016, and the re­la­tion­ship has proved fruit­ful for the biotech that just went pub­lic a lit­tle over a month ago.

But the Swiss Phar­ma is now punt­ing on one of the pro­tein degra­da­tion pro­grams in the part­ner­ship. Roche is hand­ing back the pro­gram tar­get­ing EGFR to C4, the biotech said Thurs­day in re­port­ing its third-quar­ter fi­nan­cials. C4 was orig­i­nal­ly no­ti­fied by Roche in June.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER